Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track VKTX with free AI briefings, catalyst countdowns, and dilution alerts.

VKTX

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$165.8M Cash on Hand

7.6mo Cash Runway

25.1% Short Interest

🧪 Upcoming Trial Catalysts

2027-07-01 · Phase 3 — Recruiting — VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
2027-07-01 · Phase 3 — Active Trial — VK2735 for Weight Management Phase 3

📊 Drug Pipeline

Drug	Indication	Phase	Status
VK2735	Weight Loss	PHASE3	ACTIVE_NOT_RECRUITING
VK2809	NASH - Nonalcoholic Steatohepatitis	PHASE2	COMPLETED
VK5211	Hip Fractures	PHASE2	COMPLETED
VK0214	Adrenomyeloneuropathy Form (AMN) of X-linked Adren	PHASE1	COMPLETED
VK2735 Drug	Weight Loss	PHASE1	COMPLETED

💰 Cash Runway & Dilution Risk

VKTX holds $165.8M in cash and burns about $65.4M/quarter from operations, giving an estimated runway of 7.6 months. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for VKTX free →

📈 Recent Insider Activity (Form 4)

Date	Insider	Type	Value
2026-03-10	Aubuchon Neil William	Purchase	$149,913
2026-01-26	Aubuchon Neil William	Purchase	$0
2026-01-05	Lian Brian	Purchase	$0
2026-01-05	Lian Brian	Purchase	$0
2026-01-05	Lian Brian	Purchase	$0

Get the full VKTX picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for VKTX and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z